A competitor of Enbrel was called Remicade, made by Janssen Biotech and approved by the FDA in 1999. It also worked by blocking TNF. But it wasn’t cheap; a story published in the New York Times when the drug was approved reported that a single treatment of Remicade cost $9,500, less than the $11,400 single-cost treatment of Enbrel.
